JPMorgan Chase & Co. Lowers Position in USANA Health Sciences, Inc. (NYSE:USNA)

JPMorgan Chase & Co. decreased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 33.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,123 shares of the company's stock after selling 9,574 shares during the quarter. JPMorgan Chase & Co. owned about 0.10% of USANA Health Sciences worth $686,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of USNA. KLP Kapitalforvaltning AS purchased a new position in shares of USANA Health Sciences during the fourth quarter valued at approximately $83,000. American Century Companies Inc. boosted its holdings in USANA Health Sciences by 12.3% during the 4th quarter. American Century Companies Inc. now owns 233,797 shares of the company's stock worth $8,391,000 after acquiring an additional 25,522 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of USANA Health Sciences in the 4th quarter worth $132,000. Royce & Associates LP raised its holdings in shares of USANA Health Sciences by 17.4% in the fourth quarter. Royce & Associates LP now owns 38,914 shares of the company's stock valued at $1,397,000 after purchasing an additional 5,771 shares during the last quarter. Finally, Pzena Investment Management LLC lifted its position in shares of USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after purchasing an additional 37,466 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Stock Performance

NYSE:USNA traded down $0.15 during mid-day trading on Monday, reaching $29.30. The stock had a trading volume of 7,441 shares, compared to its average volume of 199,528. USANA Health Sciences, Inc. has a one year low of $23.10 and a one year high of $49.78. The firm has a 50 day moving average price of $27.48 and a two-hundred day moving average price of $32.90. The stock has a market capitalization of $552.50 million, a P/E ratio of 10.35, a P/E/G ratio of 0.93 and a beta of 0.60.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $249.54 million during the quarter, compared to analyst estimates of $243.08 million. During the same period in the prior year, the business posted $0.86 earnings per share. Research analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on USNA shares. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. DA Davidson dropped their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th.

Insider Buying and Selling at USANA Health Sciences

In other news, CEO Jim Brown sold 5,000 shares of USANA Health Sciences stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the sale, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the transaction, the insider now directly owns 12,775 shares in the company, valued at $421,319.50. This trade represents a 20.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,920 shares of company stock valued at $500,285 in the last quarter. Company insiders own 0.63% of the company's stock.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.